Literature DB >> 17296344

The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance.

Stephen C Woods1.   

Abstract

Scientific interest in the endocannabinoid (EC) system developed as a result of the known effects of tetrahydrocannabinol, including an increased desire to consume food. Further investigation has led to the belief that the EC system plays a role in accumulation of intra-abdominal fat and worsening of cardiovascular disease (CVD) risk factors. The EC system has been identified as a neuromodulatory system that is normally inactive but can be overstimulated to cause and exacerbate numerous metabolic pathologies. EC agonists and receptors have been identified in the brain, liver, and peripheral adipose tissue, and the EC system is known to affect metabolism in these areas and others through neuromodulatory signals. Meal size, body weight, and numerous metabolic factors such as triglyceride and cholesterol levels, insulin resistance, and glucose intolerance can be affected via the EC system. Further research into the EC system is warranted to elucidate its role in metabolic homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296344     DOI: 10.1016/j.amjmed.2006.11.013

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  The endocannabinoid system: a new pharmacological target for obesity treatment?

Authors:  Jia Hu; Chao Zhu; Mao Huang
Journal:  Neurosci Bull       Date:  2009-06       Impact factor: 5.203

2.  The Effect of Cannabis-Based Medicine in the Treatment of Cachexia: A Systematic Review and Meta-Analysis.

Authors:  Samuel Hammond; Simon Erridge; Nagina Mangal; Barbara Pacchetti; Mikael H Sodergren
Journal:  Cannabis Cannabinoid Res       Date:  2021-10-18

Review 3.  Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.

Authors:  Tim C M A Schreuder; Bart J Verwer; Carin M J van Nieuwkerk; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 4.  Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.

Authors:  Jennifer B Green; Mark N Feinglos
Journal:  Curr Diab Rep       Date:  2007-10       Impact factor: 4.810

5.  Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis.

Authors:  Annarosa Floreani; Roberta Lazzari; Veronica Macchi; Andrea Porzionato; Angela Variola; Davide Colavito; Alberta Leon; Maria Guido; Vincenzo Baldo; Raffaele De Caro; Nora V Bergasa
Journal:  J Gastroenterol       Date:  2010       Impact factor: 7.527

6.  Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms.

Authors:  Christoph Buettner; Evan D Muse; Andrew Cheng; Linghong Chen; Thomas Scherer; Alessandro Pocai; Kai Su; Bob Cheng; Xiasong Li; Judith Harvey-White; Gary J Schwartz; George Kunos; Luciano Rossetti; Christoph Buettner
Journal:  Nat Med       Date:  2008-06-01       Impact factor: 53.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.